Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspire ends denufosol retinal program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Inspire discontinues its Phase II pilot trials of the P2Y2 agonist denufosol (INS37217) for macular edema "and has no plans to conduct any further studies of denufosol for the treatment of retinal disease," the firm says Jan. 20. Data in two studies "did not demonstrate improvement in either reduction or retinal thickness or improvement in visual acuity." While the trials have been halted, Inspire will follow treated patients for one year. The company announced Jan. 30 that it is moving denufosol into Phase III for treatment of cystic fibrosis. Inspire has another P2Y2 agent, diquafosol, which is "approvable" for dry eye (1Pharmaceutical Approvals Monthly December 2005, p. 5)...

You may also be interested in...



Pfizer, Allergan And Schering NMEs Receive Second “Approvable” Letters

Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel